Clinical trials: Zoledronic acid
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Breast Cancer, Hypercalcemia of Malignancy
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
RATIONALE: Ibandronate and zoledronate may help relieve some of the symptoms caused by bone metastases. It is not yet know whether ibandronate is more effective than zoledronate in treating bone metastases from breast cancer.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer
- Trial name
- NCT00326820
- Testing
- ibandronate sodium, zoledronic acid, Zolendronic Acid
- Where
- 79 sites in United Kingdom
- Volunteers
- 1,404 people
- Sponsor
- Wales Cancer Trials Unit
Osteoporotic Fractures, Osteoporosis, Postmenopausal
Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
- Trial name
- ZEST II (NCT02589600)
- Testing
- Zoledronic acid, vitamin D, calcium
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- Susan L. Greenspan
Multiple Myeloma
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
To evaluate the safety and tolerability of intravenous zoledronic acid in the treatment of patients with multiple myeloma stage III with bone lesions related to Cancer.
- Trial name
- NCT00242528
- Testing
- Zoledronic acid
- Sponsor
- Novartis
Osteoporosis in Post-menopausal Women
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Osteoporosis is associated with a high risk of fractures, disability, loss of independence, and excess mortality. Zoledronic acid is an established first-line treatment in Sweden, but many patients at high fracture risk remain at…
- Trial name
- STRONG-HIP (NCT07772609)
- Testing
- Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU
- Where
- 9 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Sahlgrenska University Hospital
Image Changes of Lumbar Fusion, Bone Turnover Markers
The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion
Many patients who have lumbar degenerative disease suffer from osteoporosis or reduced bone mass or low bone mineral density. Among patients with lumbar degenerative disease, some need fusion surgery.
- Conditions
- Image Changes of Lumbar Fusion, Bone Turnover Markers, Bone Mineral Density
- Trial name
- NCT01310465
- Testing
- zoledronic acid, sodium chloride
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Osteoporosis, Prostate Cancer
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
RATIONALE: Zoledronate may prevent bone loss in patients with prostate cancer undergoing radiation therapy and hormone therapy. It is not yet known whether zoledronate is more effective than calcium and vitamin D alone in…
- Trial name
- NCT00329797
- Testing
- Calcium, Zoledronic acid, radiation therapy
- Where
- 88 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
The purpose of this study is to evaluate the effect of zoledronic acid and physical activity on preventing bone loss in women aged 40 - 55 who are receiving chemotherapy for breast cancer.
- Trial name
- NCT00202059
- Testing
- Zoledronic acid, Physical activity intervention
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- HealthPartners Institute
Bone Fragile, Bisphosphonate-Associated Osteonecrosis
Efficacy and Safety on the Use of Bisphosphonates in Paediatrics
The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.
- Conditions
- Bone Fragile, Bisphosphonate-Associated Osteonecrosis, Children, Adverse Events
- Trial name
- Bisphosphonate (NCT04012320)
- Testing
- No intervention, observational study
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Post-Menopausal Osteoporosis
Intra-venous Zoledronic Acid Once Yearly
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment.
- Trial name
- IVORY (NCT00984893)
- Testing
- zoledronic acid, Any oral bisphosphonates marketed in Canada
- Where
- 3 sites in Canada
- Volunteers
- 1,551 people
- Sponsor
- Novartis Pharmaceuticals
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Prostate Cancer
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
This study is being conducted to compare the effect of an investigational drug versus placebo on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT).
- Trial name
- NCT00087659
- Testing
- zoledronic acid
- Where
- 16 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171314
- Testing
- Zoledronic acid, Letrozole
- Where
- 49 sites in Argentina, Belgium and 7 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals
Disuse Osteoporosis
Zoledronic Acid Administration in Acute Spinal Cord Injury
In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA).
- Trial name
- NCT02042872
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable…
- Trial name
- NCT05866172
- Testing
- HAIC, Zoledronic acid
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
RATIONALE: Calcitriol may help prostate cancer cells develop into normal cells. Zoledronate may delay or prevent the formation of bone metastases.
- Trial name
- NCT00004928
- Testing
- calcitriol, zoledronic acid
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoarthritis, Hip
The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip
Hip Osteoarthritis (OA) is one of the most common diseases affecting the ageing population. No specific and safe treatment slowing the development of hip OA as reflected in reduced joint space narrowing has been developed so far.
- Trial name
- NCT04303026
- Testing
- Zoledronic Acid, Saline 0.9%
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Vestre Viken Hospital Trust
Breast Cancer, Prostate Cancer
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System.
- Conditions
- Breast Cancer, Prostate Cancer, Metastasis
- Trial name
- REaCT-BTA (NCT02721433)
- Testing
- Pamidronate, Denosumab, Zoledronate
- Where
- Canada
- Volunteers
- 263 people
- Sponsor
- Ottawa Hospital Research Institute
Multiple Myeloma
Stage I Multiple Myeloma Treatment
Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate.
- Trial name
- IFM-01-04 (NCT00733538)
- Testing
- zometa
- Where
- France
- Volunteers
- 89 people
- Sponsor
- Centre Hospitalier Universitaire de Nice